Holen Sie sich die Stockscreener-App
1.32
0.75%
-0.01
Handel nachbörslich:
1.32
MAIA Biotechnology Inc Aktie (MAIA) Neueste Nachrichten
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
MAIA Biotechnology, Inc. SEC Filing (Aug 31, 2026) - Stock Titan
MAIA Biotechnology Inc. (MAIA) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Maia Biotechnology director Guerrero buys $2,386 in common stock By Investing.com - Investing.com India
MAIA (MAIA) Latest: Declines 0.07% to $1.38 in the Latest Session; Chart Watch: the Session Ends Within the Reported Technical Boundaries at the CloseDouble Top - vinanet.vn
MAIA Biotechnology Q3 EPS Forecast Lowered by Diamond Equity - MarketBeat
MAIA (MAIA) Q2 2026 Results: EPS Does Not Reach the Reported Estimate on the Day; Post-Earnings: The Stock Records a 3.28% Increase in the Current UpdatePositive Surprise Momentum - vinanet.vn
Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA) - Yahoo Finance
Centric Wealth Management Takes Position in MAIA Biotechnology, Inc. $MAIA - MarketBeat
Solas Capital discloses 4.9% MAIA Biotechnology (MAIA) stake in Schedule 13G/A - Stock Titan
MAIA Q2 2026 Earnings: Wider-than-Expected Loss Highlights Pre-Revenue Biotech Challenges - Vinanet
Maia Biotechnology Inc (MAIA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
MAIA Biotechnology Q2 Results: EPS misses estimates - scanx.trade
MAIA Biotechnology 6M 2026: Net loss $(14.31M), Diluted EPS $(0.27) — 10-Q Summary - TradingView
MAIA Biotechnology (MAIA) Projected to Release Earnings on Monday - MarketBeat
MAIA Biotechnology Q1 2026 Earnings: EPS Beats Estimates, No Revenue ReportedDividend Growth Analysis - dars.gov.et
MAIA Biotechnology, Inc. Revenue Breakdown – AMEX:MAIA - TradingView
MAIA|Maia Biotechnology Inc|Price:1.255|Chg%:+0.005 - TradingKey
Maia Biotechnology Inc (MAIA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Maia Biotechnology Inc (MAIA) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Maia Biotechnology Inc (MAIA) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Maia Biotechnology Inc (MAIA) Institutional Confidence - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.240|Chg%:-0.040 - TradingKey
Maia Biotechnology Inc (MAIA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Maia Biotechnology Inc (MAIA) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
MAIA Biotechnology (MAIA) Gains 3.23% as Shares Push Toward $1.28 Resistance LevelAnalyst Upgrade Stocks - vinanet.vn
Maia Biotechnology Inc (MAIA) Risk Assessment: Volatility, Financial Risk & Investment Risk - tradingkey.com
Maia Biotechnology Inc (MAIA) Valuation: PE, PB & Fair Value Analysis - TradingKey
MAIA|Maia Biotechnology Inc|Price:1.290|Chg%:+0.050 - TradingKey
Maia Biotechnology Inc (MAIA) Cash Flow - TradingKey
MAIA Q1 2026 Earnings: Narrower Loss Beats Estimates, But Stock DeclinesBasic EPS Analysis - vinanet.vn
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations Amid Pipeline ProgressDividend Cut Risk - vinanet.vn
MAIA Q1 2026 Earnings: EPS Beat on Reduced Net Loss, Stock GainsNet Income Trends - vinanet.vn
MAIA Biotechnology Edges Lower as Support Level Faces TestVol Target Rebalance - Bölüm Sonu Canavarı
MAIA Biotechnology Inc. (MAIA) Slides 1.37% as Stock Tests Key Support LevelEarnings Sentiment - dars.gov.et
Noble Financial Sticks to Their Buy Rating for MAIA Biotechnology, Inc. (MAIA) - The Globe and Mail
MAIA Biotechnology Inc. (MAIA) Holds Near Support as Trading Volumes Remain SubduedOption Strike Build - dars.gov.et
Data released by MAIA Biotechnology Inc. show that the combination therapy of its candidate drug Apatganosin with Ximiprilizumab demonstrated an acceptable safety profile in a heavily pre-treated population of patients with advanced solid tumors. - Bitget
Maia Biotechnology Reports Initial Efficacy Data from Phase 2 Thio-101 Part C Expansion Trial in Third-Line Non-Small Cell Lung Cancer - marketscreener.com
MAIA Biotechnology Reports Strong Initial Efficacy Data in Third-Line Non-Small Cell Lung Cancer from Phase 2 THIO-101 Part C Expansion Trial - The Manila Times
MAIA Biotechnology Reports 90.5% Interim Disease Control Rate in Phase 2 THIO-101 Part C for Advanced NSCLC - Quiver Quantitative
MAIA Biotechnology Reports Strong Initial Efficacy Data in - GlobeNewswire
MAIA Biotechnology (MAIA) Faces Selling Pressure as Shares Approach Key SupportIPO Entry Watch - dars.gov.et
MAIA Biotechnology Inc. (MAIA) Rises 3.1% as Shares Approach Key ResistanceVolume Profile - DonanımHaber
Enterprise value to EBITDA forward of MAIA Biotechnology, Inc. – AMEX:MAIA - TradingView
Price to earnings forward of MAIA Biotechnology, Inc. – BOATS:MAIA - TradingView
MAIAMAIA Biotechnology Inc Dividends - Finviz
ETFs Investing in MAIA Biotechnology, Inc. Stocks - TradingView
MAIA Biotechnology (MAIA) director receives grant of 26,982 stock options - Stock Titan
MAIA Biotechnology (MAIA) director awarded 26,355 stock options at $1.44 - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director receives 32,630 stock options grant - Stock Titan
MAIA Biotechnology (NASDAQ: MAIA) director granted 27,610 stock options at $1.44 strike - Stock Titan
Director at MAIA Biotechnology (MAIA) receives 32,003 stock options grant - Stock Titan
26,355 stock options granted to MAIA (NASDAQ: MAIA) director Jean-Manasse - Stock Titan
MAIA Q1 2026 Earnings: Narrower Loss Beats Expectations as Clinical Pipeline AdvancesRevenue Report - dars.gov.et
MAIA Forecast — Price Target — Prediction for 2027 - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (AMEX:MAIA) - TradingView
MAIA Biotechnology, Inc. Actuals & Estimates (BOATS:MAIA) - TradingView
Why Is MAIA Biotechnology (NYSE:MAIA) Tracking Higher on Trial News? - Kalkine Media
MAIA finishes THIO-101 enrollment abroad, with 41 lung cancer patients treated - Stock Titan
Why Gold Prices Are CrashingACT NOW! Vincenzo Italiano (pm3QIbzhx7) - Fathom Journal
MAIA Biotechnology Completes International Enrollment in Part C of Phase 2 THIO-101 Expansion Trial in Third-Line Non-Small Cell Lung Cancer - Barchart.com
MAIA Biotechnology (MAIA) Edges Higher Amid Biotech Sector Interest — Key Levels in FocusBackspread Trade - dars.gov.et
Noble Financial Maintains MAIA Biotechnology(MAIA.US) With Buy Rating, Maintains Target Price $14 - Moomoo
MAIA Should I Buy - Intellectia AI
MAIA Gains on Setting up New Site - Baystreet.ca
MAIA Biotechnology Opens Enrollment for Phase 2 Expansion - GlobeNewswire
0.86%
0.31%
Kapitalisierung:
|
Volumen (24h):